ArticleDiscover mental health2026
Elevated cortisol in patients with type 2 diabetes mellitus and comorbid depressive symptoms is associated with poor glycemic control and reduced insulin levels.
Article in Discover mental health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes and depression are highly prevalent chronic conditions, and their comorbidity further impacts quality of life and disease outcomes. Cortisol, the primary stress hormone and a diabetogenic hormone, plays a potential role in linking these conditions. Chronic stress may lead to persistently elevated cortisol levels, which may influence metabolic activity and glycemic control. This study aimed to determine the prevalence and severity of depressive symptoms among patients with type 2 diabetes and to evaluate the association of cortisol levels with depressive symptom severity and glycemic control.
methodsIn this case-control study, we recruited 100 individuals without diabetes and 200 diagnosed patients with type 2 diabetes. Participants were screened for clinically significant depressive and anxiety symptoms using the Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A), respectively. Morning cortisol levels were measured, and their associations with depressive symptom severity and glycemic control were evaluated in patients with type 2 diabetes.
resultsThe prevalence of clinically significant depressive symptoms was higher in patients with type 2 diabetes compared to individuals without diabetes (38% vs. 13%, p < 0.001). Similarly, clinically significant anxiety symptoms were more frequent in patients with type 2 diabetes (14.5% vs. 9%, p = 0.03). Mean cortisol levels were significantly higher in patients with type 2 diabetes (p < 0.001). Among patients with type 2 diabetes, those with severe depressive symptoms had higher cortisol and HbA1c levels and lower insulin levels (p < 0.05). Longer diabetes duration and exclusive insulin therapy were associated with less favorable metabolic profiles. Independent predictors of hypercortisolism included moderate-to-severe depressive symptoms, elevated HbA1c, longer disease duration, insulin therapy, and diabetic complications.
conclusionIn patients with type 2 diabetes and comorbid depressive symptoms, higher cortisol levels were associated with poorer glycemic control and lower insulin levels, particularly in those with severe depressive symptoms. These findings support the importance of incorporating mental health screening into diabetes care for better disease management.
Indexed as
Identifiers
42406228What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.